Resumen

Introduction Invasive fungal infection continues to exact a high cost in terms of morbidity and mortality, despite considerable progress in diagnosis and therapy in the latter stages of the last century. Disseminated disease may result in respiratory failure, neurological impairment, or loss of vision, to name just a few of the more common complications, while the survival rate from invasive aspergillosis is less than 20% in some patient groups1. It is, therefore, not surprising that attempts have been made, over the years, to improve the outcome of therapy by combining existing antifungal agents. A PubMed search using the terms “combination antifungal therapy” produces a list of more than 10,000 papers, although the numbers appear to have plateaued over the last few years. Many of these are reports of in-vitro studies of agents unlikely ever to be used for treating human invasive fungal infections; but even searching for clinical reviews on this topic reveals more than 1500 articles, demonstrating the importance of this concept and the high level of interest in it.

Palabras clave:

2013-02-11   |   444 visitas   |   Evalua este artículo 0 valoraciones

Vol. 16 Núm.3. Diciembre 2012 Pags. 3-10 Infectio 2012; 16(Supl 3)